Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P23786: Variant p.Ser113Leu

Carnitine O-palmitoyltransferase 2, mitochondrial
Gene: CPT2
Feedback?
Variant information Variant position: help 113 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Serine (S) to Leucine (L) at position 113 (S113L, p.Ser113Leu). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from small size and polar (S) to medium size and hydrophobic (L) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In CPT2D; muscular form; frequent mutation. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 113 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 658 The length of the canonical sequence.
Location on the sequence: help KELHEQLVALDKQNKHTSYI S GPWFDMYLSARDSVVLNFNP The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         KELHEQLVALDKQNKHTSYISGPWFDMYLSARDSVVLNFNP

Mouse                         KELHAHLLAQDKQNKHTSYISGPWFDMYLTARDSVVLNFNP

Rat                           KELHAHLLAQDKQNKHTSYISGPWFDMYLTARDSIVLNFNP

Bovine                        KELHEQLVTQDKQNKHTSYISGPWFDMYLTARDPVVLNFNP

Xenopus laevis                KQLHEELVQQDKQNKHTSYISGPWFDMYLCARDSIVLNSNP

Xenopus tropicalis            KQLHEELVQQDKQNKHTSYISGPWFDMYLCARESIVLNFNP

Zebrafish                     KQLHEELVALDKKNKHTSYISAPWFDMYLSARESIVLNFNP
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 26 – 658 Carnitine O-palmitoyltransferase 2, mitochondrial
Topological domain 26 – 178 Mitochondrial matrix



Literature citations
The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).
The MGC Project Team;
Genome Res. 14:2121-2127(2004)
Cited for: NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]; VARIANT CPT2D LEU-113; VARIANTS ILE-368 AND VAL-647; Identification of a common mutation in the carnitine palmitoyltransferase II gene in familial recurrent myoglobinuria patients.
Taroni F.; Verderio E.; Dworzak F.; Willems P.J.; Cavadini P.; Didonato S.;
Nat. Genet. 4:314-320(1993)
Cited for: VARIANT CPT2D LEU-113; Identification of four novel mutations in patients with carnitine palmitoyltransferase II (CPT II) deficiency.
Yang B.-Z.; Ding J.-H.; Dewese T.; Roe D.; He G.; Wilkinson J.; Day D.W.; Demaugre F.; Rabier D.; Brivet M.; Roe C.;
Mol. Genet. Metab. 64:229-236(1998)
Cited for: VARIANTS CPT2D LEU-113; GLN-151; LEU-227; ARG-550 AND SER-604; VARIANTS ILE-368 AND VAL-647; Fuel utilization in subjects with carnitine palmitoyltransferase 2 gene mutations.
Oerngreen M.C.; Dunoe M.; Ejstrup R.; Christensen E.; Schwartz M.; Sacchetti M.; Vissing J.;
Ann. Neurol. 57:60-66(2005)
Cited for: VARIANTS CPT2D HIS-50; LEU-113 AND GLY-213;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.